Bone Mineral Density Substudy - An Ancillary Study to MTN-003
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The MTN-003 HIV prevention study include the use of microbicides, substances that kill
microbes, and tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir disoproxil
fumarate (FTC/TDF) - oral, FDA-approved, anti-HIV drugs. The purpose of this study is to
determine if taking daily TDF and FTC/TDF as a part of the study MTN-003 has an effect on
bone mineral density (BMD).
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Microbicide Trials Network
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir